Early experience of prostate artery embolization: a retrospective single-centre study
DOI:
https://doi.org/10.2340/sju.v60.42495Keywords:
Prostate artery embolization, benign prostatic hyperplasia, lower urinary tract symptoms, International Prostate Symptom ScoreAbstract
Objective: The aim of this study was to evaluate the early experiences of prostate artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
Material and methods: This retrospective study included all patients treated for BPH who were referred to the radiology department for PAE in Västmanland between 2018 and 2021. Data were collected on patient demographics, International Prostate Symptom Score (IPSS), prostate-specific antigen level, and peri- and post-procedure outcomes. Clinical success was defined as a decrease in the IPSS by ≤3 points or catheter freedom.
Results: A total of 96 patients (median age 74 years) underwent PAE. Before PAE, 65% of the patients were treated with α-blockers and 83% with 5α-reductase inhibitors. Clinical success was achieved in 60 patients (63%). Among catheterized patients, 33 (53%) achieved catheter freedom. In the non-catheterized group, 27 (79%) experienced clinical success. No significant differences in outcomes were observed based on the presence of a median lobe.
Conclusions: PAE appears to be a viable treatment option for BPH and may provide substantial symptom relief and catheter freedom for most patients. These findings suggest that PAE may be an effective alternative to more invasive procedures. Further research is needed to refine the patient selection criteria.
Downloads
References
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms. Urol Clin North Am. 2016;43:289–297. https://doi.org/10.1016/j.ucl.2016.04.001 DOI: https://doi.org/10.1016/j.ucl.2016.04.001
Stranne J, Damber J, Fall M, et al. One-third of the Swedish male population over 50 years of age suffers from lower urinary tract symptoms. Scand J Urol Nephrol. 2009;43:199–205. https://doi.org/10.1080/00365590902833747 DOI: https://doi.org/10.1080/00365590902833747
Åkerla J, Pesonen JS, Peltonen E, et al. Do men adapt to lower urinary tract symptoms? An 11-year longitudinal study of male urinary urgency and associated bother. Scand J Urol. 2024;59:47–53. https://doi.org/10.2340/sju.v59.18289 DOI: https://doi.org/10.2340/sju.v59.18289
Partin AW, Dmochowski RR, Kavoussi LR, et al., editors. Campbell-Walsh-Wein urology. 12th ed. Philadelphia, PA: Elsevier; 2020.
Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006;175(3S):S19–S24. https://doi.org/10.1016/S0022-5347(05)00310-1 DOI: https://doi.org/10.1016/S0022-5347(05)00310-1
Sciacqua LV, Vanzulli A, Di Meo R, et al. Minimally invasive treatment in benign prostatic hyperplasia (BPH). Technol Cancer Res Treat. 2023;22:153303382311550. https://doi.org/10.1177/15330338231155000 DOI: https://doi.org/10.1177/15330338231155000
Salmivalli A, Boström P, Nurminen P, et al. National trends of surgery for benign prostatic hyperplasia in Finland. Scand J Urol. 2024;59:70–75. https://doi.org/10.2340/sju.v59.32425 DOI: https://doi.org/10.2340/sju.v59.32425
Juliebø-Jones P, Nøss Haugland J, Tzelves L, et al. Adverse events associated with Urolift: findings from the US MAUDE registry. Scand J Urol. 2023;58(Suppl. 222):12.
Li M, Qiu J, Hou Q, et al. Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0121265. https://doi.org/10.1371/journal.pone.0121265 DOI: https://doi.org/10.1371/journal.pone.0121265
Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50:969–980. https://doi.org/10.1016/j.eururo.2005.12.042 DOI: https://doi.org/10.1016/j.eururo.2005.12.042
Schneidewind L, Kranz J, Schlager D, et al. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. Cent Eur J Urol. 2017;70(1):112–117.
Sagen E, Namnuan R-O, Hedelin H, et al. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system. Scand J Urol. 2019;53:240–245. https://doi.org/10.1080/21681805.2019.1623312 DOI: https://doi.org/10.1080/21681805.2019.1623312
Serretta V, Morgia G, Fondacaro L, et al. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology. 2002;60:623–627. https://doi.org/10.1016/S0090-4295(02)01860-5 DOI: https://doi.org/10.1016/S0090-4295(02)01860-5
Swärd J, Bohlin K, Henrikson O, et al. Long-term efficacy of selective arterial embolisation of renal angiomyolipoma. Scand J Urol. 2023;58:86–92. https://doi.org/10.2340/sju.v58.12318 DOI: https://doi.org/10.2340/sju.v58.12318
Marshburn PB, Matthews ML, Hurst BS. Uterine artery embolization as a treatment option for uterine myomas. Obstet Gynecol Clin North Am. 2006;33:125–144. https://doi.org/10.1016/j.ogc.2005.12.009 DOI: https://doi.org/10.1016/j.ogc.2005.12.009
Carnevale FC, Antunes AA, Da Motta Leal Filho JM, et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33:355–361. https://doi.org/10.1007/s00270-009-9727-z DOI: https://doi.org/10.1007/s00270-009-9727-z
Bertolo R, Cipriani C, Giuliani MS, et al. Prostatic arterial embolization as a micro-invasive treatment option for benign prostatic obstruction: a subtle balance between short-term follow-up patient-reported outcomes and de-obstructive effectiveness. Front Urol. 2022;2:960875. https://doi.org/10.3389/fruro.2022.960875 DOI: https://doi.org/10.3389/fruro.2022.960875
Xhepa G, Sciacqua LV, Vanzulli A, et al. Prostate artery embolization (PAE) with small beads for the treatment of benign prostatic hyperplasia (BPH). J Pers Med. 2024;14:613. https://doi.org/10.3390/jpm14060613 DOI: https://doi.org/10.3390/jpm14060613
Gil R, Shim DJ, Kim D, et al. Prostatic artery embolization for lower urinary tract symptoms via transradial versus transfemoral artery access: single-center technical outcomes. Korean J Radiol. 2022;23:548. https://doi.org/10.3348/kjr.2021.0934 DOI: https://doi.org/10.3348/kjr.2021.0934
Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, et al. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–542. https://doi.org/10.1016/j.jvir.2012.12.019 DOI: https://doi.org/10.1016/j.jvir.2012.12.019
Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients? J Urol. 1995;154:1770–1774. https://doi.org/10.1016/S0022-5347(01)66780-6 DOI: https://doi.org/10.1016/S0022-5347(01)66780-6
Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED Technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37:1602–1605. https://doi.org/10.1007/s00270-014-0908-z DOI: https://doi.org/10.1007/s00270-014-0908-z
R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
Gohel, D., & Skintzos, P. (2024). flextable: Functions for Tabular Reporting. R package version 0.9.7. Retrieved from https://davidgohel.github.io/flextable/.
Sjoberg, D. D., Whiting, K., Curry, M., Lavery, J. A., & Larmarange, J. (2021). Reproducible Summary Tables with the gtsummary Package. The R Journal, 13(1), 570–580. https://doi.org/10.32614/RJ-2021-053. DOI: https://doi.org/10.32614/RJ-2021-053
Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686. https://doi.org/10.21105/joss.01686 DOI: https://doi.org/10.21105/joss.01686
Cardarelli-Leite L, de Assis AM, Moreira AM, et al. Impact of 5-alpha-reductase inhibitors use at the time of prostatic artery embolization for treatment of benign prostatic obstruction. J Vasc Interv Radiol. 2019;30:228–232. https://doi.org/10.1016/j.jvir.2018.11.027 DOI: https://doi.org/10.1016/j.jvir.2018.11.027
Gravas S, Cornu JN, Drake M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) 2018. Eur Assoc Urol Guidel 2018 Ed. In EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) 2018. Arnhem: European Association of Urology Guidelines Office; 2018.
Bohlok J, Söderberg R, Patschan O. Transurethral versus open enucleation of the prostate in Sweden – a retrospective comparative cohort study. Scand J Urol. 2023;58:126–132. https://doi.org/10.2340/sju.v58.15327 DOI: https://doi.org/10.2340/sju.v58.15327
Stenmark F, Brundin L, Gunnarsson O, et al. A randomised study of TURP after intraprostatic injection of mepicacaine/adrenaline versus regular TURP in patients with LUTS/BPO. Scand J Urol. 2023;58:46–51. https://doi.org/10.2340/sju.v58.7798 DOI: https://doi.org/10.2340/sju.v58.7798
Lindgren H, Bläckberg M. Introduction of prostate artery embolization (PAE) in Sweden. Scand J Urol. 2019;53:151–155. https://doi.org/10.1080/21681805.2019.1610494 DOI: https://doi.org/10.1080/21681805.2019.1610494
Pisco J, Campos Pinheiro L, Bilhim T, et al. Prostatic arterial embolization for benign prostatic hyperplasia: Short- and intermediate-term results. Radiology. 2013;266:668–677. https://doi.org/10.1148/radiol.12111601 DOI: https://doi.org/10.1148/radiol.12111601
Yu SCH, Cho CCM, Hung EHY, et al. Thickness-to-height ratio of intravesical prostatic protrusion predicts the clinical outcome and morbidity of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2019;30:1807–1816. https://doi.org/10.1016/j.jvir.2019.07.035 DOI: https://doi.org/10.1016/j.jvir.2019.07.035
Stenmark F, Brudin L, Kjölhede H, et al. Treatment with CoreTherm in 570 patients with prostate volumes of 80–366 ml: an evaluation of short- and long-term retreatment risk. Scand J Urol. 2022;56:336–341. https://doi.org/10.1080/21681805.2022.2108139 DOI: https://doi.org/10.1080/21681805.2022.2108139
Published
How to Cite
License
Copyright (c) 2025 Emir Majbar, Jakob Swanberg, Farhood Alamdari, Ralph Peeker, Abbas Chabok
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
